Squarepoint Ops LLC Has $724,000 Position in Vanda Pharmaceuticals Inc. $VNDA

Squarepoint Ops LLC raised its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 96.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 153,345 shares of the biopharmaceutical company’s stock after acquiring an additional 75,295 shares during the quarter. Squarepoint Ops LLC owned about 0.26% of Vanda Pharmaceuticals worth $724,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Millennium Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Geode Capital Management LLC increased its position in Vanda Pharmaceuticals by 4.8% during the second quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after buying an additional 77,997 shares during the last quarter. Krensavage Asset Management LLC raised its holdings in Vanda Pharmaceuticals by 35.9% during the second quarter. Krensavage Asset Management LLC now owns 1,024,883 shares of the biopharmaceutical company’s stock valued at $4,837,000 after buying an additional 270,502 shares in the last quarter. Marshall Wace LLP raised its holdings in Vanda Pharmaceuticals by 945.9% during the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock valued at $2,227,000 after buying an additional 426,620 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter worth about $2,022,000. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Stock Down 2.7%

VNDA opened at $6.84 on Wednesday. The business has a 50 day moving average of $5.35 and a 200-day moving average of $4.93. The stock has a market capitalization of $404.24 million, a price-to-earnings ratio of -4.82 and a beta of 0.69. The company has a current ratio of 3.12, a quick ratio of 3.10 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $7.20.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative return on equity of 16.82% and a negative net margin of 39.70%.The company had revenue of $56.26 million for the quarter, compared to the consensus estimate of $58.73 million. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VNDA shares. Wall Street Zen lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, December 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, December 17th. Finally, B. Riley assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, November 5th. They issued a “buy” rating and a $11.00 target price on the stock. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $14.00.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.